Exton, PA, July 08, 2026 (GLOBE NEWSWIRE) -- The European market for metabolic dysfunction-associated steatohepatitis (MASH) is entering a pivotal phase of development as increasing disease recognition converges with the recent approvals of Madrigal’s Rezdiffra (resmetirom) and Novo Nordisk’s Kayshild…